Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pollen Allergy-Pipeline Review, H1 2015

Pollen Allergy-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pollen Allergy-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pollen Allergy-Pipeline Review, H1 2015', provides an overview of the Pollen Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pollen Allergy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pollen Allergy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pollen Allergy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pollen Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Pollen Allergy Overview 10

Therapeutics Development 11

Pipeline Products for Pollen Allergy-Overview 11

Pipeline Products for Pollen Allergy-Comparative Analysis 12

Pollen Allergy-Therapeutics under Development by Companies 13

Pollen Allergy-Therapeutics under Investigation by Universities/Institutes 15

Pollen Allergy-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Pollen Allergy-Products under Development by Companies 19

Pollen Allergy-Products under Investigation by Universities/Institutes 22

Pollen Allergy-Companies Involved in Therapeutics Development 23

ALK-Abello A/S 23

Allergopharma Joachim Ganzer KG 24

Allergy Therapeutics plc 25

Anergis SA 26

Biomay AG 27

BioTech Tools s.a. 28

Circassia Pharmaceuticals plc 29

HAL Allergy BV 30

Immunomic Therapeutics, Inc. 31

Japan Tobacco Inc. 32

Laboratorios LETI S.L. 33

REGiMMUNE Corporation 34

Roxall Medizin GmbH 35

Stallergenes S.A. 36

Pollen Allergy-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Combination Products 38

Assessment by Target 39

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

ALK Birch Pollen Vaccine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

AllerG-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Allergen Extract Of Phleum Pratense-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

AllerJ-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

AllerT-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ASP-4070-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Avanz Phleum Pratense-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Birch-SPIRE-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BM-31-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

BM-32-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

clustoid wiesenlieschgras-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Drug for Birch Pollen Allergy-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Drug for Japanese Cedar Pollen Allergy-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Drugs for Cedar Pollen Allergy-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

gpASIT + TM-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

grass allergy vaccine-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Japanese cedar hypoallergenic vaccine-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

JCC-LAMP-Vax-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

MC-LAMP-Vax-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Multi-LAMP-Vax-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

PL-102-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Pollinex Quattro Grass-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Pollinex Quattro Japanese Cedar-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Pollinex Quattro Tree-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

rBet v1-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

rBet v1-FV-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

RGI-1001-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

timothy grass pollen allergen extract-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

TO-206-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Vaccine for Cedar Pollen Allergy-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Vaccine for Cedar Pollen Allergy-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Vaccine for Pollen Allergy-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Pollen Allergy-Recent Pipeline Updates 86

Pollen Allergy-Dormant Projects 93

Pollen Allergy-Discontinued Products 95

Pollen Allergy-Product Development Milestones 96

Featured News & Press Releases 96

Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 96

Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 96

Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 97

Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 98

Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 98

Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 99

Feb 27, 2014: Phase IIb Results of Anergis Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 99

Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 100

Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 100

Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 101

Appendix 102

Methodology 102

Coverage 102

Secondary Research 102

Primary Research 102

Expert Panel Validation 102

Contact Us 102

Disclaimer 103

List of Tables

Number of Products under Development for Pollen Allergy, H1 2015 11

Number of Products under Development for Pollen Allergy-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Development by Companies, H1 2015 (Contd..2) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Pollen Allergy-Pipeline by ALK-Abello A/S, H1 2015 23

Pollen Allergy-Pipeline by Allergopharma Joachim Ganzer KG, H1 2015 24

Pollen Allergy-Pipeline by Allergy Therapeutics plc, H1 2015 25

Pollen Allergy-Pipeline by Anergis SA, H1 2015 26

Pollen Allergy-Pipeline by Biomay AG, H1 2015 27

Pollen Allergy-Pipeline by BioTech Tools s.a., H1 2015 28

Pollen Allergy-Pipeline by Circassia Pharmaceuticals plc, H1 2015 29

Pollen Allergy-Pipeline by HAL Allergy BV, H1 2015 30

Pollen Allergy-Pipeline by Immunomic Therapeutics, Inc., H1 2015 31

Pollen Allergy-Pipeline by Japan Tobacco Inc., H1 2015 32

Pollen Allergy-Pipeline by Laboratorios LETI S.L., H1 2015 33

Pollen Allergy-Pipeline by REGiMMUNE Corporation, H1 2015 34

Pollen Allergy-Pipeline by Roxall Medizin GmbH, H1 2015 35

Pollen Allergy-Pipeline by Stallergenes S.A., H1 2015 36

Assessment by Monotherapy Products, H1 2015 37

Assessment by Combination Products, H1 2015 38

Number of Products by Stage and Target, H1 2015 39

Number of Products by Stage and Route of Administration, H1 2015 41

Number of Products by Stage and Molecule Type, H1 2015 43

Pollen Allergy Therapeutics-Recent Pipeline Updates, H1 2015 86

Pollen Allergy-Dormant Projects, H1 2015 93

Pollen Allergy-Dormant Projects (Contd..1), H1 2015 94

Pollen Allergy-Discontinued Products, H1 2015 95

List of Figures

Number of Products under Development for Pollen Allergy, H1 2015 11

Number of Products under Development for Pollen Allergy-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 37

Number of Products by Stage and Top 10 Targets, H1 2015 39

Number of Products by Top 10 Routes of Administration, H1 2015 40

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 41

Number of Products by Top 10 Molecule Types, H1 2015 42

Number of Products by Stage and Top 10 Molecule Types, H1 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ALK-Abello A/S

Allergopharma Joachim Ganzer KG

Allergy Therapeutics plc

Anergis SA

Biomay AG

BioTech Tools s.a.

Circassia Pharmaceuticals plc

HAL Allergy BV

Immunomic Therapeutics, Inc.

Japan Tobacco Inc.

Laboratorios LETI S.L.

REGiMMUNE Corporation

Roxall Medizin GmbH

Stallergenes S.A.

Pollen Allergy Therapeutic Products under Development, Key Players in Pollen Allergy Therapeutics, Pollen Allergy Pipeline Overview, Pollen Allergy Pipeline, Pollen Allergy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com